Gastrointestinal Symptoms and Elevated Levels of Anti-Saccharomyces cerevisiae Antibodies Are Associated with Higher Disease Activity in Colombian Patients with Spondyloarthritis
Table 1
Social and demographic description.
SpA
AS+
uSpA+
ReA+
IBD
HS
( = 102)
( = 29)
( = 58)
( = 15)
( = 29)
( = 117)
Age
42.2 ± 15.1
48.4 ± 16.5
38.1 ± 13.3
37.3 ± 13.6
48.7 ± 13.3
41.2 ± 13.3
Gender (male)
42 (40.7)
18 (62.1)
35 (60.3)
7 (46.7)
16 (50.0)
55 (47)
Weight
69.9 ± 12.6
73.9 ± 11.6
69.5 ± 12.1
63 ± 13.7
72.8 ± 13.6
67.5 ± 12.9
HLA-B27
40 (39.6)
17 (60.7)
18 (32.7)
5 (33.3)
N/A
5(4)
BASFI > 4
60 (60.6)
18 (62.1)
38 (66.0)
8 (53.3)
N/A
N/A
BASDAI > 4
67 (67.7)
19 (62.1)
41 (70.7)
11 (73.3)
N/A
N/A
ESR > 20 mm3/h
39 (39.4)
17 (60.7)
20 (34.5)
7 (46.7)
26.7 (23.5)
9.9 (10.0)
CRP > 3 mg/Dl
9 (9.6)
28 (96.6)
53 (91.4)
14 (93.3)
2.05 (3.5)
3.73 (4.8)
IgA (mg/dL)
272 (210–372)
251 (214–383)
272 (197–377)
270 (164–353)
329 (233–442)
274 (210–355)
Treatment
NSAIDS
24 (24.5)
5 (17.2)
17 (31.5)
1 (7.1)
None
N/A
Sulfasalazine
8 (8.2)
1 (3.4)
6 (11.1)
2 (7.1)
1 (3.4)
N/A
Anti-TNF
24 (24.5)
9 (31.0)
10 (18.5)
5 (35.7)
4 (13.7)
N/A
Combination with anti-TNF
23 (23.5)
8 (27.6)
10 (18.5)
5 (35.7)
1 (3.4)
N/A
Sulfasalazine + NSAID
19 (19.4)
6 (20.7)
11 (20.4)
2 (14.3)
None
N/A
Mesalazine
None
None
None
None
21 (72.4)
N/A
Results expressed as (%). Results expressed as mean ± standard deviation. Results expressed as median (interquartile range). BASFI: Bath Ankylosing Spondylitis Functional Index, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, Anti-TNF: antitumor necrosis factor, NSAID: nonsteroid anti-inflammatory drugs; N/A: not applied, < 0.05. +Diagnosis at the beginning of SpA diseases.
